Topotecan-d6

CAT: 0804-HY-13768S1-01Size: 500 µgDry Ice: NoHazardous: No
CAT#:0804-HY-13768S1-01Size:500 µg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Topotecan-d6 is the deuterium labeled Topotecan. Topotecan (SKF 104864A; NSC 609669) is a Topoisomerase I inhibitor. The IC50 values of Topotecan at 24 h are 2.73±0.25 μM of U251 cells, 2.95±0.23 μM of U87 cells, 5.46±0.41 μM of GSCs-U251 and 5.95 μM of GSCs-U87[1][2].
CAS Number
[1044904-10-0]
UNSPSC
12352005
Hazard Statement
H301
Target
Autophagy; Isotope-Labeled Compounds; Topoisomerase
Type
Isotope-Labeled Compounds
Related Pathways
Autophagy; Cell Cycle/DNA Damage; Others
Field of Research
Cancer
Purity
94.0
Solubility
10 mM in DMSO
Smiles
CC[C@@]1(C2=C(COC1=O)C(N3C(C(C(C3)=CC4=C5CN(C([2H])([2H])[2H])C([2H])([2H])[2H])=NC4=CC=C5O)=C2)=O)O
Molecular Formula
C23H17D6N3O5
Molecular Weight
427.48
Precautions
H301
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Zhang FL, et al. PLoS One. 2013 Nov 26;8 (11) :e81815.Topoisomerase I inhibitors, Shikonin and Topotecan, inhibit growth and induce apoptosis of glioma cells andglioma stem cells.|[3]Kumar S, et al. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin Cancer Res. 2011 Sep 1;17 (17) :5656-67.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Popular Products